Hemorrhagic Transformation of Ischemic Stroke: Prediction with CT Perfusion

被引:133
作者
Aviv, Richard I. [3 ]
d'Esterre, Christopher D. [1 ,2 ]
Murphy, Blake D. [1 ,2 ]
Hopyan, Julia J. [4 ]
Buck, Brian [6 ]
Mallia, Gabriella [3 ]
Li, Vivian [3 ]
Zhang, Liying [5 ]
Symons, Sean P. [3 ]
Lee, Ting-Yim [1 ,2 ]
机构
[1] Univ Western Ontario, Robarts Res Inst, London, ON N6A 5K9, Canada
[2] Univ Western Ontario, Lawson Hlth Res Ctr, London, ON N6A 5K9, Canada
[3] Sunnybrook Hlth Sci Ctr, Div Neuroradiol, Toronto, ON M4N 3M5, Canada
[4] Sunnybrook Hlth Sci Ctr, Div Neurol, Toronto, ON M4N 3M5, Canada
[5] Sunnybrook Hlth Sci Ctr, Dept Clin Trials & Epidemiol, Odette Canc Ctr, Toronto, ON M4N 3M5, Canada
[6] Grey Nuns Hosp, Reg Stroke Program, Edmonton, AB, Canada
关键词
TISSUE-PLASMINOGEN ACTIVATOR; BRAIN-BARRIER DISRUPTION; COOPERATIVE ACUTE STROKE; INTRAARTERIAL THROMBOLYSIS; COMPUTED-TOMOGRAPHY; BLOOD-FLOW; MICROVASCULAR PERMEABILITY; INTRAVENOUS THROMBOLYSIS; EARLY REPERFUSION; INFARCT CORE;
D O I
10.1148/radiol.2503080257
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose: To determine whether admission computed tomography (CT) perfusion-derived permeability-surface area product (PS) maps differ between patients with hemorrhagic acute stroke and those with nonhemorrhagic acute stroke. Materials and Methods: This prospective study was institutional review board approved, and all participants gave written informed consent. Forty-one patients who presented with acute stroke within 3 hours after stroke symptom onset underwent two-phase CT perfusion imaging, which enabled PS measurement. Patients were assigned to groups according to whether they had hemorrhage transformation (HT) at follow-up magnetic resonance (MR) imaging and CT and/or whether they received tissue plasminogen activator (TPA) treatment. Clinical, demographic, and CT perfusion variables were compared between the HT and non-HT patient groups. Associations between PS and HT were tested at univariate and multivariate logistic regression analyses and receiver operating characteristic (ROC) analysis. Results: HT developed in 23 (56%) patients. Patients with HT had higher National Institutes of Health Stroke Scale (NIHSS) scores (P = .005), poorer outcomes (P = .001), and a higher likelihood of having received TPA (P = .005) compared with patients without HT. Baseline blood flow (P = .17) and blood volume (P = .11) defects and extent of flow reduction (P = .27) were comparable between the two groups. The mean PS for the HT group, 0.49 mL . min(-1) . (100 g)(-1), was significantly higher than that for the non-HT group, 0.09 mL . min(-1) . (100 g)(-1) (P < .0001). PS (odds ratio, 3.5; 95% confidence interval [CI]: 1.69, 7.06; P = .0007) and size of hypoattenuating area at nonenhanced admission CT (odds ratio, 0.4; 95% CI: 0.2, 0.7; P = .002) were the only independent variables associated with HT at stepwise multivariate analysis. The mean area under the ROC curve was 0.918 (95% CI: 0.828, 1.00). The PS threshold of 0.23 mL . min(-1) . (100g)(-1) had 77% sensitivity and 94% specificity for detection of HT. Conclusion: Admission PS measurement appears promising for distinguishing patients with acute stroke who are likely from those who are not likely to develop HT. (c) RSNA, 2009
引用
收藏
页码:867 / 877
页数:11
相关论文
共 50 条
[11]   Asymptomatic hemorrhage after thrombolysis may not be benign - Prognosis by hemorrhage type in the Canadian Alteplase for Stroke Effectiveness Study registry [J].
Dzialowski, Imanuel ;
Pexman, J. H. Warwick ;
Barber, Philip A. ;
Demchuk, Andrew M. ;
Buchan, Alastair M. ;
Hill, Michael D. .
STROKE, 2007, 38 (01) :75-79
[12]   Hemorrhagic transformation within 36 hours of a cerebral infarct - Relationships with early clinical deterioration and 3-month outcome in the European Cooperative Acute Stroke Study I (ECASS I) cohort [J].
Fiorelli, M ;
Bastianello, S ;
von Kummer, R ;
del Zoppo, GJ ;
Larrue, V ;
Lesaffre, E ;
Ringleb, AP ;
Lorenzano, S ;
Manelfe, C ;
Bozzao, L .
STROKE, 1999, 30 (11) :2280-2284
[13]  
FISHER M, 1951, J NEUROPATH EXP NEUR, V10, P92
[14]   Intra-arterial prourokinase for acute ischemic stroke - The PROACT II study: A randomized controlled trial [J].
Furlan, A ;
Higashida, R ;
Wechsler, L ;
Gent, M ;
Rowley, H ;
Kase, C ;
Pessin, M ;
Ahuja, A ;
Callahan, F ;
Clark, WM ;
Silver, F ;
Rivera, F .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (21) :2003-2011
[15]   The Desmoteplase In Acute Ischemic Stroke Trial (DIAS) - A phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase [J].
Hacke, W ;
Albers, G ;
Al-Rawi, Y ;
Bogousslavsky, J ;
Davalos, A ;
Eliasziw, M ;
Fischer, M ;
Furlan, A ;
Kaste, M ;
Lees, KR ;
Soehngen, M ;
Warach, S .
STROKE, 2005, 36 (01) :66-73
[16]   Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II) [J].
Hacke, W ;
Kaste, M ;
Fieschi, C ;
von Kummer, R ;
Davalos, A ;
Meier, D ;
Larrue, V ;
Bluhmki, E ;
Davis, S ;
Donnan, G ;
Schneider, D ;
Diez-Tejedor, E ;
Trouillas, P .
LANCET, 1998, 352 (9136) :1245-1251
[17]  
HACKE W, 1995, JAMA-J AM MED ASSOC, V274, P1017, DOI 10.1001/jama.274.13.1017
[18]  
Hacke W, 2004, LANCET, V363, P768
[19]   MICROVASCULAR BASAL LAMINA ANTIGENS DISAPPEAR DURING CEREBRAL-ISCHEMIA AND REPERFUSION [J].
HAMANN, GF ;
OKADA, Y ;
FITRIDGE, R ;
DELZOPPO, GJ .
STROKE, 1995, 26 (11) :2120-2126
[20]   DELAYED HIGH-DOSE CONTRAST CT - IDENTIFYING PATIENTS AT RISK OF MASSIVE HEMORRHAGIC INFARCTION [J].
HAYMAN, LA ;
EVANS, RA ;
BASTION, FO ;
HINCK, VC .
AMERICAN JOURNAL OF ROENTGENOLOGY, 1981, 136 (06) :1151-1159